Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

NASDAQ:HSCS - Nasdaq - US42254E3027 - Common Stock - Currency: USD

3.38  -0.12 (-3.43%)

Fundamental Rating

2

Taking everything into account, HSCS scores 2 out of 10 in our fundamental rating. HSCS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. HSCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSCS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HSCS has reported negative net income.
In the past year HSCS has reported a negative cash flow from operations.
In the past 5 years HSCS always reported negative net income.
In the past 5 years HSCS always reported negative operating cash flow.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

HSCS has a worse Return On Assets (-207.56%) than 92.51% of its industry peers.
The Return On Equity of HSCS (-4271.54%) is worse than 93.05% of its industry peers.
Industry RankSector Rank
ROA -207.56%
ROE -4271.54%
ROIC N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 56.82%, HSCS is in line with its industry, outperforming 55.08% of the companies in the same industry.
In the last couple of years the Gross Margin of HSCS has grown nicely.
The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

More info and screens

4

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HSCS has more shares outstanding
The number of shares outstanding for HSCS has been reduced compared to 5 years ago.
Compared to 1 year ago, HSCS has a worse debt to assets ratio.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

HSCS has an Altman-Z score of -31.19. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
HSCS has a worse Altman-Z score (-31.19) than 89.84% of its industry peers.
There is no outstanding debt for HSCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -31.19
ROIC/WACCN/A
WACC8.02%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

A Current Ratio of 0.59 indicates that HSCS may have some problems paying its short term obligations.
HSCS's Current ratio of 0.59 is on the low side compared to the rest of the industry. HSCS is outperformed by 94.12% of its industry peers.
A Quick Ratio of 0.41 indicates that HSCS may have some problems paying its short term obligations.
HSCS has a Quick ratio of 0.41. This is amonst the worse of the industry: HSCS underperforms 93.58% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.41
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

HSCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.58%, which is quite impressive.
Looking at the last year, HSCS shows a very negative growth in Revenue. The Revenue has decreased by -76.34% in the last year.
The Revenue for HSCS have been decreasing by -41.50% on average. This is quite bad
EPS 1Y (TTM)81.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.01%
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A

3.2 Future

HSCS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.27% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y19.47%
EPS Next 2Y30.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M 5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

HSCS's earnings are expected to grow with 30.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.27%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEARTSCIENCES INC

NASDAQ:HSCS (8/15/2025, 8:27:17 PM)

3.38

-0.12 (-3.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-24 2025-07-24/amc
Earnings (Next)09-11 2025-09-11
Inst Owners1.55%
Inst Owner Change49.37%
Ins Owners1.97%
Ins Owner Change-16.78%
Market Cap6.52M
Analysts82.5
Price Target13.26 (292.31%)
Short Float %13.45%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.89%
Min EPS beat(2)-6.31%
Max EPS beat(2)18.08%
EPS beat(4)2
Avg EPS beat(4)3.8%
Min EPS beat(4)-6.31%
Max EPS beat(4)18.08%
EPS beat(8)4
Avg EPS beat(8)-47.81%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.7%
EPS NQ rev (3m)-1.7%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1482.59
P/FCF N/A
P/OCF N/A
P/B 31.79
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.36
EYN/A
EPS(NY)-7.54
Fwd EYN/A
FCF(TTM)-3.86
FCFYN/A
OCF(TTM)-3.84
OCFYN/A
SpS0
BVpS0.11
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -207.56%
ROE -4271.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.82%
FCFM N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.32%
Cap/Sales 686.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.41
Altman-Z -31.19
F-Score2
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)199.15%
Cap/Depr(5y)121.34%
Cap/Sales(3y)570.65%
Cap/Sales(5y)345.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.01%
EPS Next Y19.47%
EPS Next 2Y30.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.12%
OCF growth 3YN/A
OCF growth 5YN/A